| Employment |
| Company: Tempus |
| Recipient: You |
| Company: Aurora Health Care |
| Recipient: You |
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Doximity |
| Recipient: You |
| Company: Tempus |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Celgene |
| Recipient: You |
| Company: VIA Oncology |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Syapse Precision Medicine Council |
| Recipient: You |
| Company: Adaptive Biotechnologies |
| Recipient: You |
| Company: Epizyme |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: Sanofi |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: TG Therapeutics |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: PrECOG |
| Recipient: Your Institution |
| Company: Strata Oncology |
| Recipient: Your Institution |
| Company: Lynx Biosciences |
| Recipient: Your Institution |
| Company: Denovo Biopharma |
| Recipient: Your Institution |
| Company: ARMO BioSciences |
| Recipient: Your Institution |
| Company: GSK |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle) |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| Company: Doximity |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
|
| Open Payments URL: https://openpaymentsdata.cms.gov/physician/192826/summary |
|